ArticleBlood2018
Open access · bronzeAbstract read
In one paragraph
Article in Blood, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 160 papers.
0numbers the graph read from it
0cells of the map it votes in
160citing papers in PubMed
7.1field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
160 citing papers in PubMed, 214 citations in OpenAlex.
- Dynamics of clonal hematopoiesis under DNA-damaging treatment in patients with ovarian cancer.Leukemia · 2024Trial
- Genomic profiling of a randomized trial of interferon-α vs hydroxyurea in MPN reveals mutation-specific responses.Blood advances · 2022Trial
- Trial
- Second primary cancers following hematologic malignancies: Epidemiology, pathobiology and clinical management.Human vaccines & immunotherapeutics · 2026Review
- Article
- Clonal Hematopoiesis and CAR T Cell Therapy: From Biological Crosstalk to Clinical Implications.International journal of laboratory hematology · 2026Review
- Cancer treatment alters mutant selection in normal esophagus.Nature genetics · 2026Article
- Targeting BIRC6 rejuvenates hematopoietic stem cell aging and immunosenescence.Signal transduction and targeted therapy · 2026Article
- Clinical management of clonal hematopoiesis.Cancer · 2026Review
- Evolution of clonal hematopoiesis during cancer treatment and its impact on outcomes.The Journal of clinical investigation · 2026Article
- Article
- VEXAS syndrome with atypical presentation: A case report and review of eosinophils in cutaneous biopsies.JAAD case reports · 2026Article
- Low-FrequencyCancers · 2026Article
- Combined inhibition of PLK4 and PPM1D promotes cell death in cancer cells with 17q amplification.Cancer cell international · 2026Article
- Clonal hematopoiesis in patients with cancer and cancer survivors: From clonal burden to cardiovascular diseases.Cancer · 2026Review
- Novel and emerging therapeutic strategies for clonal hematopoiesis.Haematologica · 2026Review
- Inflammageing and clonal haematopoiesis interplay and their impact on human disease.Nature reviews. Molecular cell biology · 2026Review
- Article
- Silent, but not innocent: the emerging role of clonal hematopoiesis in predicting therapy-related myeloid neoplasms.Frontiers in oncology · 2026Review
- Analysis and Interpretation of Somatic NMD-Escaping Variants in Oncogenes and Dual-Function Genes across Adult and Pediatric Cancer Cohorts.medRxiv : the preprint server for health sciences · 2025Article
100 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
18 authors at 6 institutions in 4 countries.
Josephine D KahnDivision of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Peter G MillerDivision of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Alexander J SilverDivision of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Rob S SellarDivision of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Shruti BhattDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Christopher GibsonBroad Institute of MIT and Harvard, Cambridge, MA.
Marie McConkeyDivision of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Dylan AdamsDivision of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Brenton MarBroad Institute of MIT and Harvard, Cambridge, MA.
Philipp MertinsProteomics Platform, Broad Institute of MIT and Harvard, Cambridge, MA.
Shaunt FereshetianProteomics Platform, Broad Institute of MIT and Harvard, Cambridge, MA.
Karsten KrugProteomics Platform, Broad Institute of MIT and Harvard, Cambridge, MA.
Haoling ZhuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Anthony LetaiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Steven A CarrBroad Institute of MIT and Harvard, Cambridge, MA.
John DoenchGenetic Perturbation Platform, Broad Institute of MIT and Harvard, Cambridge, MA; and.
Siddhartha JaiswalDivision of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Benjamin L EbertDivision of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Brigham and Women's Hospital · USBroad Institute · USHarvard University · USDana-Farber Cancer Institute · USBerlin Institute of Health at Charité - Universitätsmedizin Berlin · DEStanford University · US
Funding
TYROSINE KINASE ONCOGENESIS IN MYELOID LEUKEMIAP01CA066996 · NCI · DANA-FARBER CANCER INSTITUTE · PI JEROME RITZ · 1996 to 2026
$52.5MTargeting SYK Kinase in AMLP50CA206963 · NCI · DANA-FARBER CANCER INST · PI ASTER, JON C. · 2017 to 2021
$10.6MSYNTHESIS OF MATERIALS WITH PHYSIOLOGICAL PROPERTIESR01GM038627 · NIGMS · YALE UNIVERSITY · PI SCHREIBER, STUART L · 1987 to 2017
$10.5MTRANSFUSION BIOLOGY AND MEDICINET32HL066987 · NHLBI · CHILDREN'S HOSPITAL BOSTON · PI JOHN P MANIS · 2001 to 2026
$10.2MTyrosine Kinases, Serine-Threonine Kinases,&Phosophatases in PathogenesisP01CA108631 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ESTEY, ELIHU · 2005 to 2009
$9.7MTraining Program in Molecular HematologyT32HL116324 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI NANCY BERLINER · 2013 to 2026
$7.4MFunctional Genomic Dissection of Refractory AnemiaR01HL082945 · NHLBI · DANA-FARBER CANCER INSTITUTE · PI EBERT, BENJAMIN LEVINE · 2005 to 2022
$6.8MHoward Hughes Medical InstituteNCI NIH HHS P01 CA066996NCI NIH HHS P01 CA108631NCI NIH HHS P50 CA206963NHLBI NIH HHS R01 HL082945NHLBI NIH HHS T32 HL066987NHLBI NIH HHS T32 HL116324NIGMS NIH HHS R01 GM038627
Abstract
Truncating mutations in the terminal exon of protein phosphatase Mg2
Indexed as
Base SequenceDrug Resistance, NeoplasmHematologic NeoplasmsMyeloproliferative DisordersNeoplasm ProteinsProtein Phosphatase 2CSequence DeletionCell Line, TumorCRISPR-Cas SystemsEnzyme InhibitorsHematopoietic Stem CellsHumansNeoplastic Stem CellsEnzyme InhibitorsNeoplasm ProteinsPPM1D protein, humanProtein Phosphatase 2C
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.